AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21846904 — intervention group
Group type: COMPARATOR
Intervention: Aerobic Training + Resistance Training (AT/RT)
Number of subjects: 196
Study 19957796 — intervention group
Group type: EXPERIMENTAL
Intervention: beta‐NGF
Number of subjects: 0
Study 19957796 — intervention group
Group type: EXPERIMENTAL
Intervention: TrKA
Number of subjects: 0
Study 19957796 — intervention group
Group type: EXPERIMENTAL
Intervention: beta‐NGF and TrKA
Number of subjects: 0
Study 19957796 — intervention group
Group type: EXPERIMENTAL
Intervention: beta‐NGF mRNA
Number of subjects: 0
Study 19957796 — intervention group
Group type: EXPERIMENTAL
Intervention: TrKA mRNA
Number of subjects: 0
Study 19957796 — intervention group
Group type: EXPERIMENTAL
Intervention: P75(NGFR) mRNA
Number of subjects: 0
Study 17426704 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU/levamisole
Number of subjects: 188
Study 17426704 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU/folinic acid
Number of subjects: 188
Study 17426704 — intervention group
Group type: EXPERIMENTAL
Intervention: p53-/BAX high
Number of subjects: 188
Study 17426704 — intervention group
Group type: EXPERIMENTAL
Intervention: BAX protein expression
Number of subjects: 188
Study 17426704 — intervention group
Group type: EXPERIMENTAL
Intervention: MSI+ tumors
Number of subjects: 188
Study 17426704 — intervention group
Group type: EXPERIMENTAL
Intervention: BAX or Bcl-2
Number of subjects: 188
Study 17426704 — intervention group
Group type: EXPERIMENTAL
Intervention: MSI
Number of subjects: 188
Study 15821379 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine 1 mg/kg
Number of subjects: 40
Study 15821379 — intervention group
Group type: COMPARATOR
Intervention: Butorphanol 0.04 mg/kg
Number of subjects: 40
Study 11508586 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymyalgia rheumatica (PMR)
Number of subjects: 28
Study 11508586 — intervention group
Group type: COMPARATOR
Intervention: Rheumatoid arthritis (RA)
Number of subjects: 28
Study 11508586 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PMR and RA)
Number of subjects: 28
Study 9778225 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pulse administration of cyclophosphamide (0.75 gm/m2)
Number of subjects: 47
Study 9778225 — intervention group
Group type: COMPARATOR
Intervention: Daily oral cyclophosphamide treatment (2 mg/kg body weight)
Number of subjects: 47
Study 8170727 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated schedule (0, 1, 2 months)
Number of subjects: 299
Study 8170727 — intervention group
Group type: COMPARATOR
Intervention: Routine schedule (0, 1, 6 months)
Number of subjects: 299
Study 29871978 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 18201
Study 29871978 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18201
Study 29871978 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin T
Number of subjects: 18201
Study 29871978 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 18201
Study 29871978 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth differentiation factor-15
Number of subjects: 18201
Study 29871978 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior stroke/systemic embolism
Number of subjects: 18201
Study 27484113 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity focused ultrasound (HIFU) treatment
Number of subjects: 40
Study 27484113 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40
Study 27484113 — intervention group
Group type: COMPARATOR
Intervention: Whole lesion ablation (comparison for treatment time)
Number of subjects: 40
Study 24964869 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored worksite‐based intelligent physical exercise training (IPET)
Number of subjects: 400
Study 22785061 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecnis toric intraocular lens (IOL)
Number of subjects: 40
Study 22785061 — intervention group
Group type: COMPARATOR
Intervention: Acrysof IQ toric IOL
Number of subjects: 40
Study 20201089 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferumoxytol (Feraheme injection) administered as two 510 mg IV injections, separated by 3-8 days
Number of subjects: 0
Study 20201089 — intervention group
Group type: COMPARATOR
Intervention: Oral iron (Ferro-Sequels) administered at a dose of 100 mg twice daily for 21 days
Number of subjects: 0
Study 20201089 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Number of subjects: 0
Study 19367170 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (150 microg orally)
Number of subjects: 60
Study 19367170 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (7.5 mg orally)
Number of subjects: 60
Study 19367170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 16721698 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone pretreatment
Number of subjects: 10
Study 16721698 — intervention group
Group type: EXPERIMENTAL
Intervention: Metyrapone pretreatment
Number of subjects: 10
Study 16721698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 16721698 — intervention group
Group type: EXPERIMENTAL
Intervention: Metyrapone with PVCs
Number of subjects: 10
Study 15702627 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 11227291 — intervention group
Group type: EXPERIMENTAL
Intervention: Certoparin (18 mg)
Number of subjects: 188
Study 11227291 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (30 mg)
Number of subjects: 188
Study 11227291 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (24 mg)
Number of subjects: 188
Study 11227291 — intervention group
Group type: COMPARATOR
Intervention: All LMWHs
Number of subjects: 188
Study 9266100 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 40 mg daily
Number of subjects: 39
Study 9266100 — intervention group
Group type: COMPARATOR
Intervention: Ovarian ablation
Number of subjects: 39
Study 8390529 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril pretreatment (5 mg/day for 5 days)
Number of subjects: 9
Study 8390529 — intervention group
Group type: COMPARATOR
Intervention: Noradrenaline (0.075 micrograms/kg per min)
Number of subjects: 9
Study 8390529 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Enalapril and Noradrenaline
Number of subjects: 9
Study 2894971 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (initial dose 2.5mg bid, titrated to 5, 10, 20mg bid)
Number of subjects: 100
Study 2894971 — intervention group
Group type: COMPARATOR
Intervention: Prazosin (initial dose 0.5mg bid, titrated to 1, 2, 4mg bid)
Number of subjects: 100
Study 31440954 — intervention group
Group type: EXPERIMENTAL
Intervention: One anastomosis gastric bypass (OAGB)
Number of subjects: 50
Study 31440954 — intervention group
Group type: COMPARATOR
Intervention: Lean controls
Number of subjects: 50
Study 31440954 — intervention group
Group type: COMPARATOR
Intervention: Patients with obesity before surgery
Number of subjects: 50
Study 31440954 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with obesity after OAGB
Number of subjects: 50
Study 31440954 — intervention group
Group type: COMPARATOR
Intervention: Patients with obesity
Number of subjects: 50
Study 30352054 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK3532795 (60 mg, 120 mg, or 180 mg QD) + TDF/FTC (300/200 mg QD)
Number of subjects: 206
Study 30352054 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz (EFV) (600 mg QD) + TDF/FTC (300/200 mg QD)
Number of subjects: 206
Study 30352054 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK3532795
Number of subjects: 206
Study 30352054 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz (EFV)
Number of subjects: 206
Study 27554946 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock delivery in asystolic patients
Number of subjects: 9902
Study 27554946 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock delivery in PEA patients
Number of subjects: 9902
Study 24482093 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin and Popular
Number of subjects: 66
Study 24482093 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin and Average Popularity
Number of subjects: 66
Study 24482093 — intervention group
Group type: COMPARATOR
Intervention: Heavy and Average Popularity
Number of subjects: 66
Study 22963595 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification for Interpretation (CBM‐I)
Number of subjects: 63
Study 22963595 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Behavioral Therapy (cCBT)
Number of subjects: 63
Study 22963595 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control group
Number of subjects: 63
Study 20526762 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg daily)
Number of subjects: 9795
Study 20526762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9795
Study 18674992 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based motor imagery gait training (15 minutes, 3 days a week for 6 weeks)
Number of subjects: 17
Study 18674992 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based motor imagery gait training
Number of subjects: 17
Study 16168145 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammographic screening
Number of subjects: 0
Study 16168145 — intervention group
Group type: COMPARATOR
Intervention: Control group not offered screening
Number of subjects: 0
Study 16168145 — intervention group
Group type: COMPARATOR
Intervention: Control group offered screening
Number of subjects: 0
Study 12608543 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin transdermal system (TDS) applied to abdomen
Number of subjects: 0
Study 12608543 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin transdermal system (TDS) applied to buttock and hip
Number of subjects: 0
Study 12608543 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin transdermal system (TDS)
Number of subjects: 0
Study 12608543 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro Oxybutynin skin absorption
Number of subjects: 0
Study 10509765 — intervention group
Group type: EXPERIMENTAL
Intervention: High-CHO diet
Number of subjects: 30
Study 10509765 — intervention group
Group type: COMPARATOR
Intervention: High-MUFA diet
Number of subjects: 30
Study 8619355 — intervention group
Group type: EXPERIMENTAL
Intervention: Iobitridol (300 mg I/ml)
Number of subjects: 80
Study 8619355 — intervention group
Group type: COMPARATOR
Intervention: Iohexol (300 mg I/ml)
Number of subjects: 80
Study 8619355 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Iobitridol and Iohexol)
Number of subjects: 80
Study 1768163 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 30 mg weekly for six weeks (Group 1)
Number of subjects: 15
Study 1768163 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 60 mg weekly for three weeks (Group 1A)
Number of subjects: 15
Study 1768163 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 45 mg every three months for one year (Group 2)
Number of subjects: 15
Study 1768163 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (both groups)
Number of subjects: 15
Study 6755247 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (Heptavax‐B)
Number of subjects: 865
Study 6755247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 865
Study 31200736 — intervention group
Group type: EXPERIMENTAL
Intervention: Shi-style lumbar manipulation (SLM)
Number of subjects: 60
Study 31200736 — intervention group
Group type: COMPARATOR
Intervention: Mechanical lumbar traction
Number of subjects: 60
Study 28433560 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla‐300)
Number of subjects: 0
Study 28433560 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine 100 U/mL (Gla‐100)
Number of subjects: 0
Study 26152000 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-limited hydrotubation combined with clomiphene citrate
Number of subjects: 80
Study 26152000 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate alone
Number of subjects: 80
Study 23567441 — intervention group
Group type: EXPERIMENTAL
Intervention: venlafaxine XR (up to 300 mg/day) for 12 weeks
Number of subjects: 277
Study 20868450 — intervention group
Group type: EXPERIMENTAL
Intervention: lipoprotein components (LDL-C, HDL-C, apoB, apoA-1, TC/HDL-C, apoB/apoA-1)
Number of subjects: 9247
Study 19299803 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous perineural femoral analgesia
Number of subjects: 217
Study 19299803 — intervention group
Group type: COMPARATOR
Intervention: Multimodal analgesia
Number of subjects: 217
Study 19299803 — intervention group
Group type: COMPARATOR
Intervention: Placebo perineural femoral infusion
Number of subjects: 217
Study 17519647 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (250 mg)
Number of subjects: 24
Study 17519647 — intervention group
Group type: COMPARATOR
Intervention: Placebo (250 mg)
Number of subjects: 24
Study 15292480 — intervention group
Group type: EXPERIMENTAL
Intervention: C&E (caffeine 70 mg/dose and ephedra 24 mg/dose)
Number of subjects: 40
Study 15292480 — intervention group
Group type: EXPERIMENTAL
Intervention: C&E
Number of subjects: 40
Study 15292480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11506984 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy elderly subjects (age 72 ± 3 years)
Number of subjects: 20
Study 11506984 — intervention group
Group type: COMPARATOR
Intervention: Healthy young subjects (age 24 ± 1 year)
Number of subjects: 20
Study 9414375 — intervention group
Group type: EXPERIMENTAL
Intervention: Keyboard and mouse with a three-dimensional arm support
Number of subjects: 20
Study 9414375 — intervention group
Group type: EXPERIMENTAL
Intervention: Trackpoint device
Number of subjects: 20
Study 9414375 — intervention group
Group type: EXPERIMENTAL
Intervention: Keyboard and mouse
Number of subjects: 20
Study 9414375 — intervention group
Group type: COMPARATOR
Intervention: Keyboard alone
Number of subjects: 20
Study 7901473 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids (40 mg prednisolone daily, tapered and stopped after 12 weeks)
Number of subjects: 136
Study 7901473 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental diet (with dietary advice on healthy eating)
Number of subjects: 136
Study 3629220 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular gold therapy
Number of subjects: 100
Study 3629220 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral penicillamine therapy
Number of subjects: 100
Study 3629220 — intervention group
Group type: COMPARATOR
Intervention: General practitioner monitoring
Number of subjects: 100
Study 31056541 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based intervention (physiotherapeutic and familial component)
Number of subjects: 42
Study 31056541 — intervention group
Group type: COMPARATOR
Intervention: Traditional early intervention
Number of subjects: 42
Study 25993585 — intervention group
Group type: COMPARATOR
Intervention: Standard CCU alarm settings
Number of subjects: 22
Study 25993585 — intervention group
Group type: EXPERIMENTAL
Intervention: Altered CCU alarm settings
Number of subjects: 22
Study 23406207 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline survey assessing genetic knowledge and attitudes toward genetic testing
Number of subjects: 300
Study 21159326 — intervention group
Group type: EXPERIMENTAL
Intervention: ePREP intervention
Number of subjects: 0
Study 21159326 — intervention group
Group type: COMPARATOR
Intervention: Placebo intervention
Number of subjects: 0
Study 18621547 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyostimulation (EMS) training for 7 weeks
Number of subjects: 25
Study 18621547 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary isometric (VOL) training for 7 weeks
Number of subjects: 25
Study 18621547 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 25
Study 16972100 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0
Study 16972100 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0
Study 15148202 — intervention group
Group type: EXPERIMENTAL
Intervention: AC IOL
Number of subjects: 110
Study 15148202 — intervention group
Group type: EXPERIMENTAL
Intervention: PC IOL
Number of subjects: 110
Study 15148202 — intervention group
Group type: COMPARATOR
Intervention: Both AC IOL and PC IOL
Number of subjects: 110
Study 12594647 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of secondary prophylaxis for PCP
Number of subjects: 146
Study 12594647 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 146
Study 9846777 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (titrated from 900 to 3600 mg/d or maximum tolerated dosage)
Number of subjects: 165
Study 9846777 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 165
Study 9846777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 7851516 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric contractions
Number of subjects: 0
Study 7851516 — intervention group
Group type: EXPERIMENTAL
Intervention: Movements against an elastic load
Number of subjects: 0
Study 7851516 — intervention group
Group type: COMPARATOR
Intervention: Isometric conditions
Number of subjects: 0
Study 2571354 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription information leaflets (PILs) for penicillins, diuretics, and benzodiazepines
Number of subjects: 252
Study 2571354 — intervention group
Group type: COMPARATOR
Intervention: No leaflets distributed (Control)
Number of subjects: 252
Study 1056849 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste with active ingredients (allantoin, pyridyl carbinol, alpha‐tocopherol, potassium aluminum sulfate, tartaric acid)
Number of subjects: 60
Study 1056849 — intervention group
Group type: COMPARATOR
Intervention: Control toothpaste without additives
Number of subjects: 60
Study 30394943 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire recall
Number of subjects: 741
Study 28982175 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal communication (IPC)
Number of subjects: 5639
Study 28982175 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated service outlets (DSO)
Number of subjects: 5639
Study 28982175 — intervention group
Group type: EXPERIMENTAL
Intervention: IPC + DSO
Number of subjects: 5639
Study 28982175 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 5639
Study 25532865 — intervention group
Group type: EXPERIMENTAL
Intervention: delta-9-THC (10 mg)
Number of subjects: 36
Study 25532865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 22841641 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment of independent pharmacies
Number of subjects: 64
Study 22841641 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment of chain pharmacies
Number of subjects: 64
Study 22841641 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall recruitment
Number of subjects: 64
Study 22841641 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist enrollment
Number of subjects: 64
Study 22841641 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy technician enrollment
Number of subjects: 64
Study 22841641 — intervention group
Group type: EXPERIMENTAL
Intervention: Median contacts per pharmacy
Number of subjects: 64
Study 22841641 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration from initial contact to consent
Number of subjects: 64
Study 22403963 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative music intervention
Number of subjects: 30
Study 22403963 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 19172289 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) training
Number of subjects: 63
Study 19172289 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 63
Study 18590259 — intervention group
Group type: EXPERIMENTAL
Intervention: DP-a (hydrofluoric acid treatment)
Number of subjects: 18
Study 18590259 — intervention group
Group type: EXPERIMENTAL
Intervention: IC-t (tribochemical silica coating)
Number of subjects: 18
Study 18590259 — intervention group
Group type: COMPARATOR
Intervention: DP-s (sandblasting treatment)
Number of subjects: 18
Study 18590259 — intervention group
Group type: COMPARATOR
Intervention: DP-t (tribochemical silica coating)
Number of subjects: 18
Study 18590259 — intervention group
Group type: COMPARATOR
Intervention: IC-s (sandblasting treatment)
Number of subjects: 18
Study 18590259 — intervention group
Group type: COMPARATOR
Intervention: IC-a (hydrofluoric acid treatment)
Number of subjects: 18
Study 15294013 — intervention group
Group type: EXPERIMENTAL
Intervention: FP/salmeterol 100/50 microg twice daily via Diskus inhaler
Number of subjects: 447
Study 15294013 — intervention group
Group type: COMPARATOR
Intervention: FP + montelukast 100 microg twice daily via Diskus inhaler plus oral montelukast 10mg once daily
Number of subjects: 447
Study 15294013 — intervention group
Group type: EXPERIMENTAL
Intervention: FP/salmeterol
Number of subjects: 447
Study 15294013 — intervention group
Group type: COMPARATOR
Intervention: FP + montelukast
Number of subjects: 447
Study 11878725 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia (TEA)
Number of subjects: 54
Study 11878725 — intervention group
Group type: COMPARATOR
Intervention: Multimodal analgesia with i.v. patient controlled analgesia (i.v. PCA)
Number of subjects: 54
Study 11878725 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia (TEA) and i.v. PCA
Number of subjects: 54
Study 9628276 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg pramlintide
Number of subjects: 11
Study 9628276 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 microg pramlintide
Number of subjects: 11
Study 9628276 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 microg pramlintide
Number of subjects: 11
Study 9628276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 7523181 — intervention group
Group type: EXPERIMENTAL
Intervention: rhG‐CSF administration
Number of subjects: 4
Study 7523181 — intervention group
Group type: COMPARATOR
Intervention: H 7 (10 mumol/l) or H 8 (20 mumol/l) co-incubation
Number of subjects: 4
Study 2536255 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg)
Number of subjects: 20